There are currently 685 clinical trials in Oklahoma City, Oklahoma looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Oklahoma Health Sciences Center, Mercy Hospital Oklahoma City, GSK Investigational Site and Lynn Health Science Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
NCT06295367
Recruiting
This clinical trial evaluates the effect of Cost Communication and Financial Navigation (CostCOM) intervention on adherence to care and financial burden in cancer patients. Many cancer patients experience financial hardship due to high medical out of pocket costs (OOPC), changes in employment, income and insurance. Financial hardship can lead to a delay or a stop in cancer care, and is linked to poor quality of life. Financial navigation programs, such as CostCOM, provide financial counseling, e... Read More
Gender:
ALL
Ages:
All
Trial Updated:
08/08/2024
Locations: Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma
Conditions: Malignant Solid Neoplasm
Register for Updates
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406
Recruiting
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma +1 locations
Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Register for Updates
Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT
NCT04678154
Recruiting
The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
08/08/2024
Locations: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
Conditions: Post Operative Surgical Site Infection
Register for Updates
Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children
NCT04509050
Recruiting
This is a two-part, multi-center, prospective longitudinal, exploratory study of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulators and their impact on children with cystic fibrosis (CF).
Gender:
ALL
Ages:
10 years and below
Trial Updated:
08/08/2024
Locations: Oklahoma Cystic Fibrosis Center, Oklahoma City, Oklahoma
Conditions: Cystic Fibrosis
Register for Updates
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359
Recruiting
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/08/2024
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma +1 locations
Conditions: Prostate Carcinoma
Register for Updates
ABTECT - Maintenance
NCT05535946
Recruiting
This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhi... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
08/06/2024
Locations: Hightower Clinical, Oklahoma City, Oklahoma +1 locations
Conditions: Ulcerative Colitis
Register for Updates
Bariatric Education for Women With Obesity and Endometrial Cancer
NCT05396794
Recruiting
The purpose of this study is to examine whether a standardized video education tool will improve knowledge regarding obesity and bariatric surgery and increase bariatric surgery referrals for obese women with endometrial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
08/01/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Obesity, Endometrial Cancer, Bariatric Surgery Candidate
Register for Updates
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT04647916
Recruiting
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: Mercy Hospital Oklahoma City, Oklahoma City, Oklahoma
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Prognostic Stage IV Breast Cancer AJCC v8
Register for Updates
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
NCT05892614
Recruiting
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: aTyr Investigative Site, Oklahoma City, Oklahoma
Conditions: Interstitial Lung Disease
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Oklahoma City, Oklahoma +1 locations
Conditions: Bipolar Depression
Register for Updates
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Hightower Clinical, Oklahoma City, Oklahoma +1 locations
Conditions: Ulcerative Colitis
Register for Updates
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
NCT05950334
Recruiting
This is a phase 1 study of FT522 administered with rituximab in participants with relapsed/refractory B-cell lymphoma (R/R BCL). The primary objectives of the study are to evaluate the safety and tolerability of FT522 in combination with rituximab, and to determine the recommended phase 2 dose (RP2D) of FT522 in combination with rituximab; each objective will be assessed with or without conditioning chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Relapsed/Refractory B-Cell Lymphoma
Register for Updates